BioSpace News Archive

The medical radiation detection, monitoring and safety market study by Fact.MR offers insights into key growth drivers and restraints impacting the growth trajectory through 2031.

Transparency Market Research has published a new report titled, ‘Asthma Spacers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global asthma spacers market was valued at US$ 1,330.56 Mn in 2017 and is projected to expand at a CAGR of 3.7% during forecast period from 2018 to 2026.

Exscientia announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.

Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in August 2021:.

Excel Diagnostics and Nuclear Oncology Center, a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug application for providing Targeted Alpha Therapy with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer.

908 Devices Inc. today reported financial results for the quarter ended June 30, 2021.

Exicure , Inc. today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET. Exicure will also host 1x1 investor meetings during the conference.

Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (T reg ) therapy and effector T cell (T eff ) conditioning

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT